“With AutoFLOW we want to make
objective MRD assessment accessible worldwide
for the optimal treatment of every child with leukaemia.”

(Michael Dworzak, MD
St. Anna Children’s Cancer Research Institute)

 

Acute Lymphoblastic Leukaemia (ALL) is the most frequent leukaemia entity in children and adolescents. Flow Cytometry (FCM) is one of the methodologies most useful in this respect, because it is widely available and applicable to most patients.

AutoFLOW aims at developing an objective and automated tool for multi-parameter FCM data analysis with specifically reliable Minimal Residual Disease (MRD) quantification to reduce the subjectivity in diagnosis and the time-consuming analysis.

NEWS:

• Check out the 1st release of the FlowVIEW auto-gating and FCM visualisation software – Try it out!